NUMD Nu-Med Plus Inc

Nu-Med Plus, Inc. announces Vice President of Medical Marketing discusses the exciting future of Nitric Oxide

Nu-Med Plus, Inc. announces Vice President of Medical Marketing discusses the exciting future of Nitric Oxide

Innovative Nu-Med Plus products provide unique low-cost systems for Nitric Oxide uses

SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- . (OTCQB: NUMD), a medical device leader developing new nitric oxide delivery technology, announces that Dr. Brett Earl, Vice President of Medical Marketing for Nu-Med Plus, recently spoke with where he discussed  the many uses of nitric oxide and Nu-Med Plus’s unique, low-cost delivery systems.

Dr. Brett Earl is Vice President of Medical Marketing for Nu-Med Plus and sits on its Board of Directors. He is a Board-Certified Emergency Physician with more than 15 years of experience in Emergency Medicine and more than a decade as a Functional Medicine Physician. He is currently the president and founder of Denali Medical Center. Dr. Earl received his medical degree from the University of Nevada- Reno. He has been published in numerous medical journals and serves on various medical boards in Utah

Jeff Robins CEO of Nu-Med Plus remarked, “Nu-Med Plus, Inc. (NUMD: OTCQB.MKTS) uses a completely different method from any of the previous processes. That's why it's been able to be patented and has implications for uses from the hospital setting to Third-World countries. The technology is sophisticated, safe, well-designed and portable. And finally, it just is much more cost effective as far as getting it into the hands of medical professionals and patients that need it.”

Inhaled nitric oxide is a medically essential gas that is currently used as a treatment for Neonate Hypoxia therapy (inadequate oxygen level in newborns), chronic obstructive pulmonary disease (COPD) and other pulmonary health issues. Precision doses of nitric oxide may have future applications for treating a variety of other diseases and complications that are currently being investigated. The Nu-Med Plus nitric oxide delivery products provide a portable, cost-effective, efficient, and user-friendly method of delivering precise therapeutic doses of nitric oxide to patients.

Media Contact:

About Nu-Med Plus, Inc.: Nu-Med Plus, Inc. founded in 2011, is a medical device development company created to explore medical applications of newly developed nitric oxide technologies. The strategy focuses on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit . Follow Nu-Med Plus on and for the latest news.

Forward-Looking Statements: Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

 

EN
26/09/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nu-Med Plus Inc

 PRESS RELEASE

Nu-Med Plus Announces Filing of U.S. Provisional Patent Application fo...

Nu-Med Plus Announces Filing of U.S. Provisional Patent Application for Nitric Oxide in Aqueous Solution for Wound Care Treatment SALT LAKE CITY, Nov. 03, 2020 (GLOBE NEWSWIRE) -- . (OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide in the medical field, today announced that the Company has filed a U.S. provisional patent application entitled, “Kinetically Controlled Method of In Situ Generation of Nitric Oxide in an Aqueous Solution.” The patent broadly covers the kinetically controlled generation of nitric oxide in an aqueo...

 PRESS RELEASE

Patent Issued for Single-Use or Short-Term Nitric Oxide Delivery Devic...

Patent Issued for Single-Use or Short-Term Nitric Oxide Delivery Device SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- . (OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide delivery in the medical field, today announced that the United States Patent and Trademark Office (“USPTO”) has issued US patent #10682486 for a single-use or short-term use nitric oxide inhaler. This patent will provide the Company the intellectual property protection to pursue individual nitric oxide treatment options in emergency situations. The Compa...

 PRESS RELEASE

Patent Issuance Allowed for Single-Use or Short-Term Nitric Oxide Del...

Patent Issuance Allowed for Single-Use or Short-Term Nitric Oxide Delivery Device SALT LAKE CITY, May 28, 2020 (GLOBE NEWSWIRE) -- . (OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide delivery in the medical field, today announced that the United States Patent and Trademark Office (“USPTO”) has allowed the issuance of a patent for a single-use or short-term use nitric oxide inhaler. This patent allowance will provide the Company the capability of providing individual nitric oxide treatment options in emergency situations, t...

 PRESS RELEASE

Nu-Med Plus Closely Monitoring Outcomes on Two New Human Clinical Tria...

Nu-Med Plus Closely Monitoring Outcomes on Two New Human Clinical Trials Using Inhaled Nitric Oxide in Treatment of COVID-19 The Company is in Current Communications with the FDA and Veterans Administration Relating to INO Technology and COVID-19 SALT LAKE CITY, March 25, 2020 (GLOBE NEWSWIRE) -- . (OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide in the medical field, today announced that the Company is closely monitoring two new clinical trials that are testing Nitric Oxide Gas Inhalation Therapy for the treatment of mild...

 PRESS RELEASE

Patent filed for Nitric Oxide Delivery Device that is comparable to in...

Patent filed for Nitric Oxide Delivery Device that is comparable to inhalers for single or short-term usage Nu-Med Plus’s Proprietary Technology is designed to open new patient markets by providing treatment options in remote and rural areas with a unique product for the generation of Nitric Oxide that has the capability to rapidly deliver the gas when serious and instantaneous use is needed. SALT LAKE CITY, Jan. 07, 2020 (GLOBE NEWSWIRE) -- . (OTCQB: NUMD), National Investment Bankers Association (NIBA) presenter Nu-Med Plus, Inc., a medical device development company announced that a ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch